argenx SE
VYVGART
primary immune thrombocytopenia (ITP)
Resolved
131days ago
Phase 3 readout · Feb 26, 2026
What's at stake
Phase 3 trial results for VYVGART in primary immune thrombocytopenia (ITP) are due Feb 26, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 11h ago
“Two Phase 3 CIDP studies highlight argenx’s commitment to advancing innovative treatment options across all adult CIDP patient populations with empasiprubart.”